VIVEbiotech Highlights Its Stable Producer Cell Line Platform for Lentiviral Vector Production

At VIVEbiotech, innovation drives our commitment to advancing lentiviral vector manufacturing for cell and gene therapies. One of our most powerful technologies is the stable producer cell line platform, designed to deliver a streamlined, reliable, and cost-effective process.

This platform is based on a HEK293T system where essential helper functions are stably integrated into the genome. After incorporating the transfer vector carrying the gene of interest, no further transfections are required—ensuring consistent performance and minimal variability.

For developers aiming for clinical and commercial success, this approach offers scalability and regulatory advantages, enabling a smooth transition from early development to GMP manufacturing.

🎥 Watch the video on YouTube or LinkedIn to learn how this platform strengthens lentiviral vector programs from concept to clinic.